B+
Bull case
25%
Probability
Target price
$33.00
+24.1% vs current
URGN
UroGenBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$27.00
+1.5% vs current
B-
Bear case
25%
Probability
Target price
$16.00
-39.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-01
Recent news sentiment (30D)
+56.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+43.8
Score
AI commentary
Primary-source evidence supports a cautious positive monitoring view rather than a high-conviction bullish call. The March 2, 2026 company release and 10-K confirmed early ZUSDURI launch traction, a defined UGN-103 NDA path, and added financing support, but forward visibility is still limited because ZUSDURI is early, 2026 product guidance is incomplete, analyst-revision evidence is sparse, and packet social coverage is unavailable. Recent headline flow also looks thin, so conviction should rest mainly on filings and company disclosures rather than sentiment spillover.
RankAlpha Sentiment Codex - 2026-05-01
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-01catalystZUSDURI post-J-code launch conversion is the near-term proof pointHigh impact
The March 2, 2026 earnings release said ZUSDURI 2025 net sales were $15.8 million and that the permanent J-code became effective on January 1, 2026, with management citing acceleration in physician uptake, 838 activated sites of care, 102 unique prescribers, and 32 repeat prescribers. The setup is constructive, but the company is still not providing 2026 ZUSDURI sales guidance, so the next few quarters need to confirm that reimbursement simplification converts into durable prescribing velocity rather than an early-launch step-up. [#8-K-2026-03-02]
2026-09-30eventUGN-103 NDA submission targeted for second half of 2026High impact
The 10-K states that UGN-103 produced a 77.8% three-month complete response rate in the Phase 3 UTOPIA trial and that the FDA agreed with the regulatory plan to support an NDA based on those data. Management said it anticipates submitting the NDA in the second half of 2026, making this the clearest pipeline value inflection in the current setup. [#10-K-2026-03-02]
2026-12-31catalystMulti-program execution and financing need to bridge to broader uro-oncology valueHigh impact
Primary sources point to several longer-cycle checkpoints: UGN-104 is expected to be fully enrolled by the end of 2026, UGN-501 IND-enabling studies are ongoing with a goal to submit an IND and start Phase 1 by year-end 2026, and the Pharmakon refinancing funded a $200 million first tranche while adding leverage. This supports runway and optionality, but it also raises the burden on management to convert commercial traction into a financeable multi-asset growth story. [#10-K-2026-03-02] [#8-K-2026-03-02]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-01 • Updated nightlySource: Internal modelMethodology